Trial Profile
A Study Assessing the Pharmacokinetics of Ponatinib and its Impact on Outcomes in Patients with Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacokinetics; Therapeutic Use
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.